Drugs / Elenbecestat
Trials 11 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 19 trials | ||||||
| Phase 1 | NCT03055962 | Feb → Mar 2017 | — | Eisai Inc. | Completed | No outcome recorded |
| Phase 1 | NCT02859207 | Aug → Dec 2016 | Alzheimer disease | Eisai Inc. | Completed | No outcome recorded |
| Phase 1 | NCT02222324 | Aug → Oct 2014 | — | Eisai Inc. | Completed | No outcome recorded |
| Phase 1 | NCT02207790 | Jul → Aug 2014 | — | Eisai Inc. | Completed | No outcome recorded |
| Phase 1 | NCT01975636 | Jun → Nov 2013 | — | Eisai Inc. | Completed | No outcome recorded |
| Phase 1 | NCT01716897 | Oct → Dec 2012 | Alzheimer disease | Eisai Inc. | Completed | No outcome recorded |
| Phase 1 | NCT01600859 | Jul 2012 → Sep 2013 | Alzheimer disease | Eisai Inc. | Completed | No outcome recorded |
| Phase 1 | NCT01511783 | Dec 2011 → Jul 2012 | — | Eisai Inc. | Completed | No outcome recorded |
| Phase 1 | NCT01294540 | Dec 2010 → Oct 2011 | Alzheimer disease | Eisai Inc. | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT02322021 | Nov 2014 → Dec 2019 | Alzheimer disease | Eisai Inc. | Terminated | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT02956486 | Oct 2016 → Jan 2020 | Alzheimer disease | Eisai Inc. | Terminated | No outcome recorded |
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02055703 Comparator | Jan → Apr 2014 | — | Eisai Inc. | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 13 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Elenbecestat | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02956486 ↗ |
| Known as | E2609 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01716897 ↗ |
| Action | Inhibit | “Beta-secretase 1 inhibitor” CHEMBL4204869 ↗ |
| Modality | Small molecule | — CHEMBL4204869 ↗ |
| Route | Oral | “E2609 orally at varying ascending doses” NCT01294540 ↗ |
| Target | BACE1 | “Beta-secretase 1 inhibitor” CHEMBL4204869 ↗ |